On May 16, 2022 PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoantigen-specific T cell receptor (neoTCR) T cell therapies for the eradication of solid tumors, reported that new data on PACT^NV, the company’s non-viral precision gene editing technology, were highlighted in a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 25th Annual Meeting (Press release, PACT Pharma, MAY 16, 2022, View Source;cell-therapy-asgct-25th-annual-meeting-301547277.html [SID1234614685]). Presented findings demonstrated the potential of the PACT^NV technology to enhance the functionality and applicability of T cell-based therapeutics, as well as other cellular therapies, through targeted gene editing. Specifically, researchers showed the ability of the versatile platform to knock-out, knock-down, knock-in and precisely regulate target genes in a single step to achieve desired activity for its neoTCR T cells. The ASGCT (Free ASGCT Whitepaper) conference is being held May 16-19, 2022, in Washington, D.C.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation reported research findings by PACT scientists demonstrating the ability to utilize the company’s PACT^NV technology to generate TCR T cells in a single step. In creating these novel patient-specific neoTCR T cells, PACT highlighted the following capabilities of its gene editing platform:
Insertion and expression of neoTCRs within T cells.
Simultaneous elimination of the expression of the endogenous TCRs within same T cells.
Knock-out of the transforming growth factor beta (TGF-β) receptor type 2 (TGFBR2) gene, generating a T cell that can both recognize a patient-specific tumor and is resistant to the immunosuppressive signaling by TGF-β.
shRNA driven knock-down of multiple additional genes without any associated double-stranded break, generating enhanced T cells that can both recognize a patient-specific tumor and, depending on the targeted transcript, possess resistance to immunosuppression, increased persistence, and/or improved functional avidity.
Development of T cell activation-induced promoters for conditional expression of payloads.
"Taken together, the powerful gene editing capabilities possessed by our PACT^NV platform offer the potential to expand the applicability of T cell therapeutics, while extending the potential use of the technology to other cellular therapies," said Stefanie Mandl, Ph.D., senior vice president, head of research at PACT Pharma. "We are particularly excited about the versatility to add, eliminate and/or precisely modulate multiple genes within our neoTCR T cells to create novel, personalized therapeutic candidates with the potential to address a range of solid tumors. We look forward to continuing our research and development efforts in support of our PACT^NV technology, while continuing our ongoing Phase 1 clinical trial of non-viral PACT^NV gene-edited autologous neoTCR T cells in advanced and metastatic solid tumors."
PACT is currently conducting a Phase 1 clinical trial evaluating the safety, tolerability and feasibility of adoptive cell therapy with its non-viral PACT^NV gene-edited autologous neoTCR T cells in advanced and metastatic solid tumors. This trial, in combination with extensive preclinical studies, has provided the company with unique data sets and insights derived from the core technologies that comprise its personalized adoptive T cell therapy platform for the treatment of solid tumors.
A copy of the poster presented at the ASGCT (Free ASGCT Whitepaper) conference is available on the "Events" page of the PACT Pharma website at: View Source